Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2026 04:13 ET | Source: Zelluna ASA

Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today...
June 30, 2026 04:13 ET | Source: Zelluna ASA

Zelluna ASA tildelt NOK 16 millioner i tilskudd fra Forskningsrådet

Oslo, 29. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene «off-the-shelf» T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer, kunngjør i dag...
June 29, 2026 07:03 ET | Source: Zelluna ASA

Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

Oslo, 29 June 2026: Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a...
June 29, 2026 03:59 ET | Source: Zelluna ASA

Zelluna ASA: New share capital registered

Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on 18 June 2026 regarding a successfully placed private placement (the...
June 29, 2026 02:30 ET | Source: Zelluna ASA

Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

The Royal Marsden NHS Foundation Trust activated as the second clinical site in the ZIMA-101 Phase 1 trialPatient identification, pre-screening and screening activities ongoing at first activated...
June 29, 2026 02:30 ET | Source: Zelluna ASA

Zelluna ASA aktiverer The Royal Marsden som det andre kliniske senteret for ZIMA-101, og utvider kapasiteten for klinisk gjennomføring

The Royal Marsden NHS Foundation Trust aktivert som det andre kliniske senteret i fase 1-studien ZIMA-101Identifisering, pre-screening og screening av pasienter er i gang ved første aktiverte kliniske...
June 26, 2026 10:40 ET | Source: Zelluna ASA

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today...
June 26, 2026 10:40 ET | Source: Zelluna ASA

Resultater fra Ultimovacs' DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan

Oslo, 26. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at den...
June 18, 2026 05:08 ET | Source: Zelluna ASA

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 18 June 2026 regarding the total allocation of 3,143,958 new shares in the Company in a private placement...
June 17, 2026 18:28 ET | Source: Zelluna ASA

Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement

Oslo, 18 June 2027: Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 17 June 2026 regarding completion of a placement of 3 143 958 new shares at a...